3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Brain Neoplasms
4
Prostatic Neoplasms
3
Neoplasms
3
Breast Neoplasms
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Pinealoma
1
Parotid Neoplasms
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Multiple Sclerosis
1
Meningioma
1
Meningeal Neoplasms
1
Medulloblastoma
1
Lymphoma
1
Liver Neoplasms
1
Hypoxia
1
Gynecologic Cancer
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Ependymoma
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Choroid Plexus Neoplasms
1
Astrocytoma
1
Interventions
lutetium Lu 177 dotatate
34
Everolimus
33
lanreotide
13
gallium Ga 68 dotatate
13
Temozolomide
13
Magnetic Resonance Spectroscopy
13
Nivolumab
12
pembrolizumab
11
Octreotide
11
Capecitabine
11
177Lu-octreotide, DOTA(0)-Tyr(3)-
10
cabozantinib
9
Positron Emission Tomography Computed Tomography
9
3-Iodobenzylguanidine
9
surufatinib
8
Sunitinib
8
Specimen Handling
7
Carboplatin
7
pasireotide
6
amino-acid, glucose, and electrolyte solution
6
90Y-octreotide, DOTA-Tyr(3)-
6
lenvatinib
5
Lutetium-177
5
Ipilimumab
5
Fluorodeoxyglucose F18
5
Etoposide
5
Cisplatin
5
Bevacizumab
5
telotristat ethyl
4
olaparib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neuroendocrine Tumors
×
gadobutrol
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled